NasdaqGM:VNDA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. More Details


Snowflake Analysis

Flawless balance sheet with moderate growth potential.


Similar Companies

Share Price & News

How has Vanda Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: VNDA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: VNDA's weekly volatility (6%) has been stable over the past year.


Market Performance


7 Day Return

0.4%

VNDA

1.9%

US Biotechs

2.1%

US Market


1 Year Return

-25.8%

VNDA

21.2%

US Biotechs

19.8%

US Market

Return vs Industry: VNDA underperformed the US Biotechs industry which returned 21.1% over the past year.

Return vs Market: VNDA underperformed the US Market which returned 19.7% over the past year.


Shareholder returns

VNDAIndustryMarket
7 Day0.4%1.9%2.1%
30 Day23.1%6.5%8.1%
90 Day19.8%7.1%6.0%
1 Year-25.8%-25.8%23.3%21.2%22.5%19.8%
3 Year-10.6%-10.6%21.7%15.4%46.5%36.8%
5 Year38.5%38.5%14.9%7.0%96.9%75.3%

Long-Term Price Volatility Vs. Market

How volatile is Vanda Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Vanda Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

34.67x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: VNDA ($12.11) is trading above our estimate of fair value ($8.46)

Significantly Below Fair Value: VNDA is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: VNDA is poor value based on its PE Ratio (33.8x) compared to the US Biotechs industry average (28.4x).

PE vs Market: VNDA is poor value based on its PE Ratio (33.8x) compared to the US market (19.7x).


Price to Earnings Growth Ratio

PEG Ratio: VNDA is good value based on its PEG Ratio (0.9x)


Price to Book Ratio

PB vs Industry: VNDA is good value based on its PB Ratio (1.5x) compared to the US Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Vanda Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

36.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: VNDA's forecast earnings growth (36.4% per year) is above the savings rate (2.2%).

Earnings vs Market: VNDA's earnings (36.4% per year) are forecast to grow faster than the US market (22% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: VNDA's revenue (7.3% per year) is forecast to grow slower than the US market (10.2% per year).

High Growth Revenue: VNDA's revenue (7.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if VNDA's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Vanda Pharmaceuticals performed over the past 5 years?

63.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: VNDA has high quality earnings.

Growing Profit Margin: VNDA's current net profit margins (8%) are lower than last year (55.4%).


Past Earnings Growth Analysis

Earnings Trend: VNDA's earnings have grown significantly by 63.6% per year over the past 5 years.

Accelerating Growth: VNDA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: VNDA had negative earnings growth (-84.1%) over the past year, making it difficult to compare to the Biotechs industry average (-8.8%).


Return on Equity

High ROE: VNDA's Return on Equity (4.4%) is considered low.


Next Steps

Financial Health

How is Vanda Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: VNDA's short term assets ($389.5M) exceed its short term liabilities ($61.4M).

Long Term Liabilities: VNDA's short term assets ($389.5M) exceed its long term liabilities ($14.0M).


Debt to Equity History and Analysis

Debt Level: VNDA is debt free.

Reducing Debt: VNDA has not had any debt for past 5 years.

Debt Coverage: VNDA has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: VNDA has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Vanda Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate VNDA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VNDA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VNDA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VNDA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VNDA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Mihael Polymeropoulos (60 yo)

17.5yrs

Tenure

US$4,278,137

Compensation

Dr. Mihael H. Polymeropoulos, M.D. founded Vanda Pharmaceuticals, Inc. in 2003 and has been its Chief Executive Officer, President and Director since May, 2003. Dr. Polymeropoulos has also been the Chief F...


CEO Compensation Analysis

Compensation vs Market: Mihael's total compensation ($USD4.28M) is above average for companies of similar size in the US market ($USD2.56M).

Compensation vs Earnings: Mihael's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Mihael Polymeropoulos
Founder17.5yrsUS$4.28m2.09%
$ 13.9m
Timothy Williams
Senior VP2.25yrsUS$2.02m0.022%
$ 143.6k
Gunther Birznieks
Senior Vice President of Business Development3.67yrsUS$2.01m0.14%
$ 901.9k
Kevin Moran
Acting CFO0.67yrno data0.027%
$ 180.1k
Aranthan Jones
Chief Corporate Affairs & Communications Officer1.25yrsno data0.00089%
$ 5.9k
Joakim Wijkstrom
Senior VP & Chief Marketing Officer1.25yrsno data0.0069%
$ 45.9k
Scott Howell
Chief People Officer1.25yrsno datano data
Elizabeth Van Every
Head of Corporate Affairsno datano datano data

1.3yrs

Average Tenure

47.5yo

Average Age

Experienced Management: VNDA's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Mihael Polymeropoulos
Founder17.5yrsUS$4.28m2.09%
$ 13.9m
Richard Dugan
Independent Director14.92yrsUS$234.99k0.065%
$ 431.6k
H. Watkins
Independent Chairman of the Board6.67yrsUS$249.33k0.055%
$ 367.2k
Anne Ward
Independent Director1.08yrsUS$270.45kno data
Stephen Mitchell
Independent Director0.75yrno data0.00037%
$ 2.5k
Phaedra Chrousos
Independent Director1.58yrsUS$545.62k0.0091%
$ 60.5k

4.1yrs

Average Tenure

63.5yo

Average Age

Experienced Board: VNDA's board of directors are considered experienced (4.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.5%.


Top Shareholders

Company Information

Vanda Pharmaceuticals Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Vanda Pharmaceuticals Inc.
  • Ticker: VNDA
  • Exchange: NasdaqGM
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$662.316m
  • Shares outstanding: 54.69m
  • Website: https://www.vandapharma.com

Number of Employees


Location

  • Vanda Pharmaceuticals Inc.
  • 2200 Pennsylvania Avenue NW
  • Suite 300E
  • Washington
  • District Of Columbia
  • 20037
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VNDANasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDApr 2006
VM4DB (Deutsche Boerse AG)YesCommon StockDEEURApr 2006
0LKBLSE (London Stock Exchange)YesCommon StockGBUSDApr 2006

Biography

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company’s marketed products include HETLIOZ f...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/27 23:52
End of Day Share Price2020/11/27 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.